Our new work is out in @EurJImmunol a big thank you to the team that made this happen: violette mouro, chiara perucchini, chiara vespari and @iannaconelab!
1/ New from our lab 🧪View quoted post on X
ARTC2 blockade is widely used to protect tissue Tregs — but when is it truly essential, and for which subsets?
2/ In this @EurJImmunol update, we dissect the subset-specific and context-dependent effects of ARTC2 blockade on hepatic Treg recovery.
3/ At steady state, ARTC2 blockade has a selective benefit: it markedly improves recovery and preserves phenotype of CD44^mid (less-activated) Tregs, while having minimal impact on effector-like eTregs.
4/ During liver inflammation, ARTC2 blockade becomes critical: it boosts overall Treg yield and prevents phenotypic distortion — again with the strongest effect on CD44^mid Tregs.
5/ Key insight: hepatic Treg subsets are not equally sensitive to ARTC2–P2RX7 activation.
Less-activated, tissue-resident Tregs are preferentially lost or skewed without protection.
6/ Practical takeaway 💡
• Studying activated/eTregs at steady state? ARTC2 blockade may be optional.
• Profiling CD44^mid Tregs or working in inflammatory settings? ARTC2 blockade is essential.
7/ Bottom line: this work reframes ARTC2 blockade from a default reagent to a rational, cost-effective experimental choice.
8/ Proud of the team — led by @CaitlinAAbbott, with @VioletteMouro and colleagues — for turning a technical challenge into actionable guidance for the field.
9/ Read the paper here 👉 onlinelibrary.wiley.com/doi/10.1002/ej…
And stay tuned — exciting new discoveries on liver Tregs are coming soon 👀🧬